PALB2 and breast cancer: Whole-exome sequencing data from 98 BRCA1/BRCA2/PALB2 founder mutation-negative Northern Finnish breast cancer cases with indications of hereditary disease susceptibility was used for the identification of rare CNVs (Fig A in S1 Text).